cas 1857296-22-0|| where to buy 5-formyl-4-methyl-1H-indole-2-carbonitrile

Nombre del producto:5-formyl-4-methyl-1H-indole-2-carbonitrile

IUPAC Name:5-formyl-4-methyl-1H-indole-2-carbonitrile

Unidad de embalaje	Stock disponible	Precio($)
CM327321-5g	in stock	ǎĜǭ
CM327321-25g	in stock	ǭĨřř

Sólo para uso en I+D..

Formulario de consulta

Nombre químico

Número CAS

Cantidad*

Especificaciones requeridas*
(% de ensayo, grado de material, etc.)

Nombre de contacto*

Correo electrónico de contacto*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 1857296-22-0 regularly via the above email.

Notas adicionales

Verification code*

refresh

: Núm. De CAS :1857296-22-0; Fórmula molecular:C11H8N2O; Punto de fusión:-; Código de sonrisas:N#CC(N1)=CC2=C1C=CC(C=O)=C2C; Densidad:

: Número de catálogo:CM327321; Peso molecular:184.2; Punto de ebullición:; Nº Mdl:; Almacenamiento:

: Indoles; Indole is a compound of pyrrole and benzene in parallel, also known as benzopyrrole. There are two combinations of pyrrole and benzene, called indole and isoindole, respectively. Many derivatives of indole have physiological and pharmacological activities, and can synthesize vasodilators, antihistamines, antipyretic analgesics, etc. in medicine, so indole is also a very important heterocyclic compound.; indole company; As a indole company,we sincerely welcome the new and old friends from home and abroad to synergize with our company and share the benefits and opportunities.

: Ziftomenib; Kura Oncology reported preliminary clinical data from the first 20 patients in KOMET-007, a Phase 1 dose-escalation trial of the Company's potent and selective menin inhibitor, ziftomenib, in combination with standards of care, including cytarabine/daunorubicin (7+3) and venetoclax/azacitidine (ven/aza), in patients with NPM1-mutant (NPM1-m) and KMT2A-rearranged (KMT2A-r) acute myeloid leukemia (AML). Ziftomenib is a novel, once-daily, oral investigational drug candidate targeting the menin-KMT2A/MLL protein-protein interaction for treatment of genetically defined AML patients with high unmet need. In preclinical models, ziftomenib inhibits the KMT2A/MLL protein complex and exhibits downstream effects on HOXA9/MEIS1 expression and potent anti-leukemic activity in genetically defined preclinical models of AML. Ziftomenib has received Orphan Drug Designation from the FDA for the treatment of AML.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.